The rapid adoption of GLP-1 receptor agonists has fundamentally altered obesity management, with these medications now ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern over the use of unapproved GLP-1 receptor agonists for weight loss, such as ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

(HealthDay News) — A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a ...

Discover how GLP-1 medications and the MAHA movement are driving protein consumption and creating new opportunities for ...

Danone has launched a drinkable yogurt product under its Oikos brand in the US targeted at users of the Ozempic and other GLP-1 weight-loss drugs. The product, called Oikos Fusion, is designed to help ...